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Abstract
In inflammatory bowel disease (IBD), tumor necro­
sis factor plays an important role in mediating infla­
mmation, but several other pathways are also involved 
in eliciting an inflammatory response. One such 
pathway is the invasion of the intestinal mucosa by 
leukocytes. Leukocytes within the systemic circulation 
move to sites of inflammation, and blocking this 
pathway could be an important treatment strategy 
for IBD. Anti­integrin therapy blocks the action of 
integrin on the surface of circulating immune cells and 
endothelial cell adhesion molecules, thereby inhibiting 
the interactions between leukocytes and intestinal blood 
vessels. Natalizumab, which acts on α4­integrin, was 
the first such drug to be approved for Crohn’s disease, 
but its use is limited due to the risk of progressive 
multifocal leukoencephalopathy. Vedolizumab produces 
few systemic adverse effects because it acts on gut­
trophic α4β7 integrin, and has been approved and is 
being used to treat IBD. Currently, several anti­integrin 
drugs, including etrolizumab, which acts on β7­integrin, 
and PF­00547569, which targets mucosal addressin cell 
adhesion molecule­1, are undergoing clinical trials and 
the results are being closely watched.
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Core tip: Anti­integrin therapies have attracted attention 
as new therapeutic agents in inflammatory bowel dis­
ease. They inhibit the extravasation of leukocytes by 
blocking the interaction between integrins on immune 
cells and endothelial cell adhesion molecules. The use 
of the first developed anti­integrin agent, natalizumab 
is now limited due to the risk of progressive multifocal 
leukoencephalopathy. However, vedolizumab which acts 
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selectively on the gut has shown few adverse events 
and is currently used in clinical practice. Newer anti­
integrin drugs that act on different integrins­related 
targets, such as AJM300, abrilumab, etrolizumab, and 
PF­00547659 have also been developed and are in 
clinical trials. 
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INTRODUCTION
Causes of inflammatory bowel disease (IBD) have not 
yet been clearly elucidated, but it is known that genetic 
susceptibility, altered gut microbiota, and environmental 
factors are all involved. It has also been reported that 
a combination of these factors causes an inappropriate 
immune response, resulting in impaired intestinal 
barrier function[1-3].
As continual research further reveals the immuno­
pathogenesis of IBD, the treatment of IBD has shifted 
from conventional treatments, such as aminosalicylates, 
glucocorticoids, and immunomodulators (thiopurines 
and methotrexate), toward the biological drugs that 
target inflammation­related pathways[4]. Anti­tumor 
necrosis factor (TNF) agents were the first biologics 
used to treat IBD, and the objective of IBD treatment 
has shifted from controlling symptoms to changing the 
progression of disease and preserving the intestinal 
function. However, anti­TNF agents are not effective in 
all IBD patients, and a considerable number of patients 
experience relapse after stopping medication. The 
pathophysiology of IBD is very complex. This means 
that the most appropriate treatment method may vary 
for each patient, and therefore, constant efforts are 
being made to develop effective drugs[4]. In particular, 
new biologics that inhibit leukocyte trafficking to the 
site of inflammation have been developed and used. 
These drugs are called anti­integrin or anti­adhesion 
agents, or leukocyte­trafficking inhibitors because 
they block the actions of integrin, a cell surface protein 
expressed by circulating immune cells and endothelial 
cell adhesion molecules (CAMs), thereby selectively 
preventing the intestinal recruitment of lymphocytes to 
the site of inflammation[5]. Thus, unlike anti­TNF drugs, 
anti­integrin agents inhibit the interactions between 
leukocytes and the intestinal vasculature, and selectively 
prevent the influx of inflammatory cells, which mediate 
the inflammatory process in IBD, into intestinal lesions. 
In this report, we aim to discuss anti­integrin therapy, 
which is currently being highlighted as a new drug 
therapy for the treatment of IBD.
NEED FOR NEW DRUGS
A variety of inflammatory and anti­inflammatory cy­
tokines define and regulate various aspects of the infla­
mmatory response and play an important role in the 
pathogenesis of IBD including Crohn’s disease (CD) 
and ulcerative colitis (UC), with the former mediated 
by type 1 T helper cells (TH1) and TH17, and the latter 
reportedly caused by an abnormal TH2 response. The 
immunopathogenesis of IBD is made more complex 
by imbalances in different T cell subsets, such as 
regulatory T cells, natural killer T cells, and TH9, as 
well as the interactions between these cell populations. 
Ultimately, the production of numerous cytokines is 
disturbed. These cytokines include the well­known 
TNF­α as well as IL­1β, IL­6, IL­8, IL­10, IL­12, IL­17, 
IL­23, and transforming growth factor­α[3,6].
The use of TNF antagonists showed that just blocking 
a single cytokine could be sufficient to induce significant 
clinical remission. Until recently, in moderate­to­severe 
active IBD patients, especially if initial treatment with 
systemic corticosteroids or immunomodulators failed, 
anti­TNF agents were the only remaining treatment 
option.
Inspired by the treatment outcomes of the first 
generation anti­TNF agent infliximab, next­generation 
TNF antagonists, such as adalimumab, golimumab, 
and certolizumab pegol, were introduced for the treat­
ment of IBD, drastically changing this treatment field; 
however, even these drugs did not show an effect in 
all IBD patients. Specifically, although reports differ 
slightly, anti­TNF agents produce primary non­response 
(PNR) in approximately 10%­30% of patients[7]. Several 
factors have been suggested as causes of PNR. One 
known cause of PNR is that TNF is not a major factor in 
the development of inflammation in some patients, and 
therefore, there is an increased need for drugs with new 
mechanisms[8].
Although anti­TNF agents show an initial effect, 
secondary non­response or loss of response (LOR) is 
seen in 23%­46%[7,9]. LOR is known to occur due to 
pharmacokinetic issues or the production of antibodies 
against the drug; however, it can also be caused by a 
shift in the inflammatory response pathway from TNF 
signaling to non­TNF signaling. Moreover, due to their 
comprehensive immunosuppressive effects, the use of 
anti­TNF agents can cause severe adverse reactions, 
including tuberculosis (TB), hepatitis B, pneumonia, 
herpes zoster, and other infections, as well as skin 
cancer, malignant lymphoma, psoriasis, lupus­like syn­
drome, demyelinating disease, congestive heart failure, 
and hepatotoxicity.
Although anti­TNF therapy has reduced the rate 
of surgery in IBD patients, a considerable number of 
patients experience a relapse of inflammation after as 
they stop anti­TNF[10]. After stopping TNF antagonist, the 
12­mo relapse rate is 40% for CD and 28% for UC[9,11]. 
Therefore, there is an urgent need for drugs with novel 
mechanisms that are more effective and safer than anti­
TNF agents, or in particular, that can be used when anti­
TNF therapy is ineffective or causes an adverse reaction.
Since biological drugs have a high molecular weight, 
they are inevitably delivered by injection, and their 
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immunogenicity leads to infusion reactions or LOR asso­
ciated with the antidrug antibody. Therefore, one aspect 
of new drug development is to focus on small molecules 
of less than 1 kDa that could be taken orally, thereby 
increasing compliance, relatively inexpensive, and have 
almost no immunogenicity, allowing them to be taken 
safely on a long­term basis.
IMMUNE CELL TRAFFICKING
Innate and adaptive immune responses depend on the 
trafficking of immune cells to the organ targeted by the 
disease. During an inflammatory response, circulating 
leukocytes migrate to the target tissues through a 
homing process that takes place in several stages. 
Migrating leukocytes in the bloodstream begin tethering 
(capture) and rolling to a specific place, through the 
activation process, arrest and adhere to vascular 
endothelial cells, and finally undergo transendothelial 
migration (Figure 1). This process of leukocytes migration 
is mediated by interactions between leukocytes and 
adhesion molecules expressed by endothelial cells, which 
enables circulating leukocytes to migrate to the target 
tissues[12]. 
Leukocytes also express CAMs on the surface, called 
integrins which allow them to interact with the vascular 
endothelial cells or other cells. Integrin is a heterodimeric 
receptor formed from α and β subunits and is divided 
into several groups depending on the structure of the α 
and β subunit, and different populations of leukocytes 
express different integrins. These integrins include α4β1 
(found on most leukocytes), α4β7 [found specifically 
on lymphocytes in the gastrointestinal (GI) tract], and 
αEβ7 (found on intraepithelial T cells, dendritic cells, 
mast cells or regulatory T cells)[13]. Integrins react with 
CAMs in the immunoglobulin (Ig) superfamily expressed 
by other cells to induce cell adhesion; α4β1, α4β7, and 
αEβ7 integrins bind to vascular cell adhesion molecule­1 
(VCAM­1) on vascular endothelial cells, mucosal 
addressin cell adhesion molecule­1 (MAdCAM­1) on 
intestinal endothelial cells, and E­cadherin on mucosal 
epithelial cells (Figure 2)[14].
The migration of leukocytes to the intestinal mucosa 
and the recruitment of immune cells to the site of in­
flammation due to increased expression of CAMs are 
essential to the development and maintenance of in­
testinal inflammation. Therefore, leukocyte trafficking 
to the gut is central to the immunopathogenesis of IBD, 
and its inhibition is recognized as an important goal in 
the development of anti­IBD drugs[5]. 
ANTI-INTEGRIN THERAPIES
Anti­integrin therapies block the action of integrins, 
expressed by circulating immune cells, on endothelial 
CAMs, thereby decreasing the trafficking of immune 
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Figure 1  Process of leukocyte migration through the endothelium. Leukocytes moving in the blood begin to tether and roll at a specific site of the vessel wall, 
undergo activation, arrest and adhesion to the vascular endothelial cells, eventually migrate between the endothelial cells.
Leukocyte
α4β7
α4β1
αEβ7
VCAM­1
MAdCAM­1
E­cadherin
Natalizumab
AJM300
Natalizumab
Endothelial cell
Endothelial cell
Epithelial cell
Etrolizumab
Vedolizumab
Abrilumab
PF­00547659
Figure 2  Therapeutic targets of anti-integrin agents[14]. VCAM-1: Vascular 
cellular adhesion molecule-1; MadCAM-1: Mucosal addressin cellular adhesion 
molecule-1.
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approximately 1 case per 1000 patients[18]. The use of 
immunomodulators before natalizumab administration, 
a positive test for anti­JC virus antibody, and longer 
duration of natalizumab treatment are risk factors for 
PML[19]. Thus, natalizumab has been approved by the 
United States. FDA only in moderate­to­severe CD 
patients who did not respond to or were intolerant of 
conventional treatment or TNF inhibitor therapy; it has 
not been approved for use in Europe.
AJM300
Despite safety issues for natalizumab, the oral α4 integrin 
antagonist AJM300 was developed and evaluated for 
use in UC. A phase Ⅱa clinical trial was conducted in 
Japan on 102 patients with moderately active UC, who 
were intolerant or showed an inappropriate response to 
mesalamine or corticosteroids; when AJM300 960 mg or 
placebo was administered 3 times per day, the primary 
end point, which was the rate of clinical response (defined 
as a decrease of at least 3 points, and at least 30% 
compared to baseline, in the complete Mayo score, 
as well as a decrease of at least 1 point for the rectal 
bleeding or an absolute rectal bleeding subscore of 1 
point or less) at week 8, was significantly higher in the 
AJM300 group, at 62.7%, than in the placebo group, at 
25.5% (P = 0.0002)[20]. Meanwhile, the clinical remission 
(defined as a complete Mayo score of 0­2 points and 
no subscore higher than 1 point) rate was 23.5% in 
the AJM300 group and 3.9% in the placebo group (P = 
0.0099), and the mucosal healing rate was 58.8% in 
the AJM300 group and 29.4% in the placebo group (P 
= 0.0014), both of which were significantly different. In 
this clinical study, serious adverse events did not occur, 
and adverse events were mild and self­limiting. However, 
considering that AJM300 shares the mechanism of 
natalizumab, and the number of subjects in this trial 
was small, and the study period was short, there are 
concerns about its practicality as a therapeutic drug. 
Nevertheless, the duration of effect for AJM300 is very 
short compared to that of natalizumab, and since it is an 
oral formulation, there is some expectation that it may 
cause fewer systemic adverse events.
cells to the endothelium and suppressing the recruit­
ment of inflammatory cells such as lymphocytes to in­
testinal lesions. Table 1 shows the anti­integrin agents 
currently approved and in use or in clinical trials.
Natalizumab
Natalizumab is a chimeric recombinant human IgG4 
antibody that targets the α4 subunit in α4β7 and α4β1 
integrins on leukocytes. α4β1 integrin interacts with 
VCAM­1. Natalizumab was first approved by the U.S. 
Food and Drug Administration (FDA) as a treatment 
for multiple sclerosis, which is an autoimmune disease 
of the central nervous system (CNS), and clinical trials 
were conducted to test its efficacy against CD.
In the phase Ⅲ Efficacy of Natalizumab in Crohn’s 
disease Response and Remission (ENCORE) trial, 509 
patients with moderate­to­severe activity and elevated 
C­reactive protein (CRP) (> 0.287 mg/dL) were allo­
cated, in a 1:1 ratio, into groups receiving either 300 
mg of natalizumab or placebo by intravenous injection 
at weeks 0, 4, and 8. The primary end point, which 
was the percentage of patients showing a clinical 
response [defined as a decrease of at least 70 points 
in CD activity index (CDAI) score] at week 8 and 
sustaining this response until week 12, was higher in 
the natalizumab group, at 48%, than in the placebo 
group, at 32% (P < 0.001)[15]. The percentage of 
patients showing sustained clinical remission (defined 
as a CDAI score under 150 points) at both week 8 and 
week 12 was also higher in the natalizumab group, at 
26%, than in the placebo group, at 16% (P = 0.002). 
However, natalizumab prevents α4β1 integrin on leuko­
cytes from binding VCAM­1 on vascular endothelial 
cells in the CNS as well as in the intestines; it has been 
reported that by reducing T cell trafficking to the brain, 
natalizumab can affect cerebral antiviral immunity, and 
in some cases, can cause a fatal brain infection called 
progressive multifocal leukoencephalopathy (PML) 
due to the reactivation of the John Cunningham (JC) 
virus[16,17]. Based on clinical trial data, the risk of PML 
after a mean of 17.9 mo of natalizumab treatment is 
Drug Formula Target Route Clinical studies Summary
Natalizumab Humanized IgG4 mAb α4-integrin i.v. ENCORE Induction and maintenance in CD
AJM300 Small molecule α4-integrin Oral Phase Ⅱa Induction in UC
Vedolizumab Humanized IgG1 mAb α4β7-integrin i.v. GEMINI 1 Induction and maintenance in UC
GEMINI 2 Induction and maintenance in CD
GEMINI 3 Induction in CD
Abrilumab (AMG 181/MEDI 7183) Fully human IgG2 mAb α4β7-integrin s.c. Phase Ⅱb Induction in UC
Phase Ⅱb Induction in CD
Etrolizumab Humanized IgG1 mAb β7-integrin i.v./s.c. EUCALYPTUS Induction in UC
BERGAMOT Induction in CD
HICKORY Induction in CD
PF-00547659 (SHP647) Fully human IgG2κ mAb MAdCAM-1 i.v./s.c. TURANDOT Induction in UC
OPERA Induction in CD
Table 1  Anti-integrin therapies for inflammatory bowel disease
IgG: Immunoglobulin; mAb: Monoclonal antibody; i.v.: Intravenous; CD: Crohn’s disease; UC: Ulcerative colitis; s.c.: Subcutaneous; MAdCAM: Mucosal 
addressin cell adhesion molecule.
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Vedolizumab
Vedolizumab (VDZ; MLN0002) is a humanized 
monoclonal IgG1 antibody against α4β7­integrin that 
inhibits the adhesion of leukocytes to the endothelium 
by blocking the interaction between α4β7­integrin and 
MAdCAM­1 expressed on blood vessels and lymph 
nodes associated with the GI tract. The main difference 
between natalizumab and VDZ is that natalizumab 
inhibits leukocyte trafficking in multiple organs, 
including the brain, whereas VDZ acts specifically only 
on gut­trophic α4β7 heterodimers, and therefore, 
inhibits lymphocyte trafficking selectively in the 
intestine. Although MAdCAM­1 exists rarely at the 
blood­brain barrier, VDZ is known to have no effect on 
CNS immunity[21]. In a study in support of this idea, 
healthy volunteers were injected VDZ and when the 
cerebrospinal fluid (CSF) was tested 5 wk later, no 
change was observed in CSF lymphocyte counts or 
CD4:CD8 ratio following VDZ administration[22]. In 
another randomized controlled trial comparing VDZ with 
a placebo, the serum antibody response to a parenteral 
hepatitis B vaccine did not differ between the 2 groups, 
but the response to an oral cholera vaccine showed 
less antibody formation in the VDZ group compared to 
the placebo group, demonstrating that while VDZ has 
no effect on systemic immunity, it decreases immune 
surveillance in the GI tract[23]. 
The phase Ⅲ GEMINI 1 trial, consisting of 2 cohorts, 
analyzed the efficacy of VDZ in 895 moderate­to­
severe UC patients who had previously received ste­
roid, immunomodulator, or anti­TNF therapy[24]. The 
374 patients in cohort 1 were randomly allocated in a 
ratio of 3:2, with each group receiving 2 intravenous 
injections of VDZ 300 mg or placebo at week 0 and 
2, and evaluated at week 6. The primary endpoint in 
the induction phase, which was the clinical response 
rate at week 6, was significantly higher in the VDZ 
group, at 47.1%, than in the placebo group, at 25.5% 
(P < 0.001). The clinical response rate at week 6 was 
also significantly higher in the VDZ group than in the 
placebo group among patients who had previously 
experienced treatment failure with anti­TNF agents 
(39.0% vs 20.6%, P = 0.01) or steroids (59.5% vs 
20.0%, P < 0.001). Moreover, the clinical remission 
rate at week 6 was 16.9% in the VDZ group and 5.4% 
in the placebo group (P = 0.001), whereas the mucosal 
healing rate at week 6 was 40.9% in the VDZ group 
and 24.8% in the placebo group (P = 0.001), and 
these differences were statistically significant. To meet 
the required sample size for the maintenance phase, 
an additional 521 patients (cohort 2) were recruited for 
an open­label trial, and administered VDZ by the same 
method. In the maintenance phase, the 373 patients 
who achieved a clinical response with VDZ at week 
6 were randomized in a 1:1:1 ratio, with each group 
receiving either a placebo, or VDZ 300 mg every four 
weeks, or every eight weeks. The trial lasted for a total 
of 52 wk. The primary endpoint in the maintenance 
phase, which was the clinical remission rate at week 
52, was 15.9% in the placebo group, 41.8% in the VDZ 
every eight weeks group, and 44.8% in the VDZ every 
four weeks group, which showed that the effect was 
2­fold higher in the VDZ groups than in the placebo 
group (P < 0.001). The durable clinical response 
(response at both week 6 and 52) was 23.8% in the 
placebo group, 56.6% in the VDZ every eight weeks 
group, and 52.0% in the VDZ every four weeks group, 
which was significantly different (P < 0.001). Similarly, 
mucosal healing at week 52 was 19.8% in the placebo 
group, 51.6% in the VDZ every eight weeks group, 
and 56.0% in the VDZ every four weeks group, which 
was also significantly different (P < 0.001). There was 
no significant difference in the efficacy of VDZ between 
the four­week and eight­week interval groups. Among 
patients who had experienced failure with anti­TNF 
therapy, the clinical remission rate was much lower 
in the placebo group, at 5.3%, than in the VDZ every 
eight weeks group, at 37.2%, and the VDZ every four 
weeks group, at 35.0% (P < 0.001). Therefore, VDZ 
demonstrated an effect against moderate­to­severe 
UC at week 6 and at week 52, irrespective of previous 
anti­TNF therapy. In the post­hoc analysis for the 
GEMINI Ⅰ trial, patients were divided into those who 
were naïve to TNF antagonist (464 patients) and failed 
to TNF antagonist (367 patients)[25]. The treatment 
effect measured by the clinical response at week 6 was 
stronger in patients who were naïve to anti­TNF therapy 
[absolute difference (AD) between VDZ and placebo 
26.4%] than in those who failed to anti­TNF therapy 
(AD 18.1%). In the maintenance phase, the ADs in 
week 52 clinical remission rates were 28.0% in patients 
who were naïve to anti­TNF therapy and 29.5% in 
patients who failed to anti­TNF therapy, respectively. 
Even among patients who had previously experienced 
failure with anti­TNF therapy, those who experienced 
LOR showed a lesser effect of VDZ than those who 
experienced PNR or intolerance. 
The GEMINI 2 trial, consisting of 2 cohorts, analyzed 
the efficacy of VDZ in active CD patients[26]. The 368 
patients in cohort 1 were randomly allocated in a 3:2 
ratio, with each group receiving intravenous VDZ 300 
mg or placebo at weeks 0 and 2, and evaluated at 
week 6. The primary endpoint, which was the clinical 
remission rate at week 6, was significantly higher in 
the VDZ group, at 14.5%, than in the placebo group, 
at 6.8% (P = 0.02). The other primary endpoint, the 
CDAI­100 response rate (defined as a decrease of at 
least 100 points in the CDAI score relative to baseline), 
was higher in the VDZ group, at 31.4%, than in the 
placebo group, at 25.7%; however, this difference was 
not statistically significant (P = 0.23). To meet the 
required sample size for the maintenance phase, an 
additional 747 patients (cohort 2) were recruited for 
an open­label trial, and administered VDZ by the same 
method. In the maintenance phase, 461 patients who 
had shown a clinical response to VDZ at week 6 which 
administered either placebo, or VDZ 300 mg every four 
weeks or every eight weeks. The primary endpoint in 
Park SC et al . Anti­integrin therapy for IBD
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the maintenance phase, which was the clinical remission 
rate at week 52, was 21.6% in the placebo group, 
39.0% in the VDZ every eight weeks group, and 36.4% 
in the VDZ every four weeks group, indicating that both 
the VDZ every eight weeks (P < 0.001) and VDZ every 
four weeks (P = 0.004) groups showed significantly 
higher clinical remission rates than the placebo group. 
Similarly, the CDAI­100 response rate at week 52 was 
30.1% in the placebo group, 43.5% in the VDZ every 
eight weeks group, and 45.5% in the VDZ every four 
weeks group, indicating that the response rate was sig­
nificantly higher in the VDZ every eight weeks group (P 
= 0.01) and the VDZ every four weeks group (P = 0.005) 
than in the placebo group. Among patients who had 
previously experienced failure with anti­TNF therapy, 
the remission rates at week 52 were 28.0%, 27.3%, 
and 12.8% for the VDZ every eight weeks, VDZ every 
four weeks, and placebo groups, respectively. This was 
significantly higher in the VDZ every eight weeks group 
(P = 0.01) and the VDZ every four weeks group (P = 
0.02) than in the placebo group.
The GEMINI 3 trial was a phase Ⅲ randomized 
controlled trial examining the efficacy and safety of VDZ 
in 416 moderate­to­severe CD patients[27]. Most of the 
participants (315 patients) had previously experienced 
failure with anti­TNF therapy (PNR, LOR, or intolerance). 
After the injection of VDZ 300 mg at weeks 0, 2, and 
6, unlike the GEMINI Ⅰ and Ⅱ trials, the effects of VDZ 
were evaluated at week 10 as well as week 6. Among 
anti­TNF­naïve patients, the clinical remission rate at 
week 6 was 12.0% in the placebo group and 31.4% in 
the VDZ group, which was significantly different (P = 
0.012). However, among patients with previous anti­
TNF therapy failure, the clinical remission rate at week 
6 was 12.1% in the placebo group and 15.2% in the 
VDZ group, which was not a statistically significant 
difference (P = 0.433), whereas the clinical remission 
rate at week 10 was significantly higher in the VDZ 
group, at 26.6%, than in the placebo group, at 12.1% 
(P = 0.001). Meanwhile, in patients with previous anti­
TNF therapy failure, the CDAI­100 response rates at 
weeks 6 and 10 were 22.3% and 24.8%, respectively, 
in the placebo group, but were significantly higher in 
the VDZ group, at 39.2% and 46.8% (P = 0.001 and P 
< 0.001, respectively). These results show that patients 
who experience anti­TNF therapy failure take longer to 
show an effect from VDZ than anti­TNF­naïve patients. 
Notably, among the subjects in this trial, patients who 
had experienced anti­TNF therapy failure had a longer 
disease duration and more structural damage than 
anti­TNF­naïve patients, which could have affected the 
clinical effects of VDZ. In the post­hoc analyses for the 
GEMINI 2 and 3 trials, for patients in the VDZ group, the 
clinical remission rate at week 52 was 48.9% in patients 
who were naïve to anti­TNF therapy and 27.7% in 
patients who had experienced anti­TNF therapy failure, 
whereas the remission rates in the placebo group were 
26.8% and 12.8%, respectively[28]. This shows that the 
clinical remission rates are higher in the VDZ group than 
in the placebo group, and that this effect is larger when 
patients have not previously been exposed to anti­TNF 
therapy. 
Vedolizumab was approved by the FDA and the Euro­
pean Medicines Agency, for the treatment of moderate to 
severe ulcerative colitis and CD adult patients which are 
not responding to one or more conventional treatment 
such as steroids, immunosuppressive agents, or TNF 
antagonists. The results of the VDZ clinical trials showed 
different treatment effects in UC and CD. There are 
several theories to explain why the clinical effect of 
inhibiting leukocyte trafficking in CD appeared later 
than that in UC. CD can show systemic manifestations 
and affect the whole GI tract from the oral cavity to the 
anus, showing inflammation in all layers of the intestine; 
conversely, UC is limited to the colonic mucosa, which 
could explain the discrepancy in the treatment response. 
Recently, a study on IBD patients and a humanized 
mouse model found that VDZ treatment in CD reduced 
the expression of α4β1 in the peripheral blood and 
increased the expression of α4β1 in the intestine, 
suggesting that in CD, the VDZ­mediated inhibition of 
α4β7 could have been circumvented by homing to the 
ileum via α4β1 on effector T cells[29]. Thus, further in­
depth research is required to better understand the 
pharmacokinetics and pharmacodynamics of VDZ in CD.
The GEMINI long­term safety (LTS) study examined 
the long­term safety and efficacy of VDZ[30,31]. Among 
patients in the phase Ⅱ trial C13004, the GEMINI 1 trial, 
and VDZ­naïve UC patients who showed a response to 
VDZ at week 6 were switched to an open­label study 
and administered VDZ 300 mg continually at four­week 
intervals for 152 wk[30]. In an interim report on the 
efficacy of VDZ, the remission rates after 104 and 152 
wk were 88% (120/136) and 96% (70/73), respectively, 
demonstrating a high maintenance of remission. Among 
patients who dropped out of the VDZ maintenance 
treatment at eight­week intervals before 52 wk in 
GEMINI Ⅰ trial (n = 32), increased dosing frequency 
to every four weeks in GEMINI LTS improved clinical 
responses and remission rates from 19% and 6% to 
41% and 28%, after 52 wk of GEMINI LTS, respectively. 
Similarly, among CD patients who had participated in 
the C13004, GEMINI 2, or GEMINI 3 trial, or were VDZ­
naïve, those who showed a response to VDZ at week 6, 
when switched to an open­label study and monitored for 
152 wk while receiving VDZ every four weeks, showed 
remission rates after 104 and 152 wk of 83% (100/120) 
and 89% (62/70), respectively[31]. Among patients 
who dropped out of the VDZ maintenance treatment at 
eight­week intervals before 52 wk in GEMINI 2 trial (n = 
57), increased dosing frequency to every four weeks in 
GEMINI LTS improved clinical responses and remission 
rates from 39% and 4% to 47% and 32%, after 52 
wk of GEMINI LTS, respectively. Therefore, for patients 
who show a response to VDZ every eight weeks in the 
induction phase, but show LOR in the maintenance 
phase, increasing the dosing frequency to every four 
weeks could produce a response again.
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To examine mucosal and histological healing 
when VDZ was administered, prospective surveillance 
colonoscopy was performed in patients registered for 
the GEMINI LTS trial[32]. The follow­up period was over 
1 year (1.1­6.1 years, median 3.2 years), the rate of 
mucosal healing with a Mayo score of 1 or less was 50% 
(17/34) for UC and 29% (7/24) for ulcer­free mucosal 
healing in CD patients. Histological healing with mucosal 
healing in UC and CD patients was 32% (11/34) and 
21% (5/24), respectively.
The VERSIFY study was examined endoscopic mu­
cosal healing at week 26 after VDZ treatment in 101 
moderate­to­severe CD patients who had previously 
experienced failure with corticosteroids, immunomodu­
lators, and/or anti­TNF agents. The endoscopic remission 
[simple endoscopic score for CD (SES­CD) ≤ 4] rate 
was 12% overall, 20% for patients who were naïve to 
anti­TNF therapy (n = 46), and 6% for patients who 
had previously experienced anti­TNF therapy failure (n 
= 55)[33]. The endoscopic response  (SES­CD decrease 
of at least 50%) and complete endoscopic healing (no 
ulcerations) rates were, respectively, 25% and 15% 
overall, 28% and 24% for patients who were naïve to 
anti­TNF therapy, and 22% and 7% for patients who 
had failed at anti­TNF therapy. Thus, VDZ is effective at 
inducing endoscopic remission and healing in refractory 
CD patients, and the rates of endoscopic remission and 
healing are higher in anti­TNF­naïve patients than in 
those who have experienced anti­TNF therapy failure.
The US VICTORY Consortium provides data relating 
to VDZ from real­world experience; among 212 mode­
rate­to­severe CD patients, 90% had exposed to anti­
TNF therapy, and the median follow­up duration was 
39 wk[34]. In responders, the median time to respond 
to VDZ was 19 wk. After 6, 12, and 18 mo of VDZ 
therapy, patients showed clinical remission rates of 18%, 
35%, and 54%, respectively, and after 6 and 12 mo of 
treatment, showed cumulative mucosal healing rates 
of 20% and 63%, respectively, and cumulative deep 
remission (clinical remission and mucosal healing) rates 
of 14% and 26%, respectively. Higher disease activity, 
active perianal disease, smoking history, and prior TNF 
antagonist exposure were all factors that decreased the 
effectiveness of VDZ.
In a German cohort study including 115 active UC 
patients and 97 active CD patients, only 24.3% of UC 
patients and 5.2% of CD patients were naïve to TNF 
antagonist[35]. When these patients were treated with 
VDZ and monitored for 14 wk, at week 14, 23.5% of 
UC patients and 23.7% of CD patients achieved clinical 
remission, 57.4% of UC patients and 60.8% of CD 
patients showed a clinical response, and steroid­free 
remission was observed in 19.1% of UC patients and 
19.6% of CD patients. Serum CRP and calprotectin 
levels were measured at weeks 0, 6, and 14; patients 
are showed decreased CRP levels, but this was not 
statistically significant, whereas calprotectin levels 
decreased significantly. 
In the GETAID Cohort Data from France, the effects 
of VDZ treatment were analyzed in 121 UC patients and 
173 CD patients who had failed with anti­TNF therapy. At 
week 6, the clinical remission rates were 32% and 31%, 
the steroid­free clinical remission rates were 21% and 
19%, and the clinical response rates were 41% and 57% 
in the UC and CD patients, respectively[36]. At week 14, 
the clinical remission rates for UC and CD patients were 
respectively 39% and 36%, the steroid­free remission 
rates were 36% and 31%, and the clinical response 
rates were 57% and 64%, demonstrating that VDZ is 
effective for both UC and CD. The fact that a superior 
treatment response was observed at week 14 compared 
to week 6 re­confirms that it takes time for the effects 
of treatment to become apparent. When patients were 
monitored for 1 year, steroid­free remission at week 
22 was 40% for UC patients and 34% for CD patients, 
indicating that remission rates gradually increased for 
both diseases, and that UC patients achieved steroid­
free remission sooner than CD patients.
In summary, real­world data for VDZ treatment 
were similar to results of randomized controlled studies. 
In particular, it takes considerable time before the 
maximal effects of VDZ therapy can be observed, and 
corticosteroid treatment may be required during this 
period. The results of a network meta­analysis show that 
VDZ is more effective overall than anti­TNF therapy in the 
maintenance phase[37]. Thus, the effect of VDZ, once it 
becomes apparent, is maintained more strongly, and this 
sustained effect is considered its greatest advantage. In 
addition, for patients showing PNR, LOR, or intolerance 
to anti­TNF therapy, it is worth considering VDZ as a 
secondary treatment (Table 2).
Because VDZ acts selectively on the intestine, it 
causes relatively little systemic immunosuppression, 
and this is expected to result in fewer adverse events. 
In the GEMINI 1 and 2 trials, the most commonly 
reported adverse reactions to VDZ (incidence ≥ 5%) 
were nausea, nasopharyngitis, upper respiratory tract 
infection, arthralgia, fever, fatigue, headache, and 
cough[24,26]. In safety data from the 6 VDZ clinical trials 
(placebo­controlled trials C13002, GEMINI 1, 2, and 3, 
and open­label trials C13004 and GEMINI LTS), VDZ 
showed no significant difference from the placebo in 
overall adverse reactions[38]. In particular, the exposure­
adjusted incidence rates of infections and serious 
infections, which is a problem in anti­TNF therapy, 
were 63.5/100 person­years (PYs) and 4.3/100 PYs in 
patients receiving VDZ, respectively, and 82.9/100 PYs 
and 3.8/100 PYs in the placebo group, respectively. 
However, the rates of gastroenteritis and Clostridium 
difficile infection were low but higher in VDZ­treated 
patients (4.0/100 PYs and 0.4/100 PYs, respectively) 
than those in the placebo group (1.4/100 PYs and 
0.0/100 PYs, respectively), and further studies will be 
required to determine whether these results are due to 
gut­selective immune suppression by VDZ. In safety 
data from the 6 VDZ clinical trials, 18 patients developed 
malignancy, including GI cancer (6 patients), skin cancer 
(5 patients), lung cancer (2 patients), genitourinary 
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cancer (2 patients), breast cancer (2 patients), and 
B cell lymphoma (1 patient). Colon cancer (0.1/100 
PYs) was the most common type of GI cancer, but its 
incidence was lower than that observed in IBD patients 
in the HealthCore Integrated Research Database 
(2.1/1000 PYs; 95%CI: 1.3­3.2)[38,39]. Infusion­related 
reactions were reported with a low incidence of less 
than 5% in patients who received VDZ[38]. VDZ does 
not affect α4β1­related nervous system leukocyte 
trafficking, and no cases of PML were observed in the 
clinical trials. Therefore, VDZ can be considered as a 
primary biological drug in elderly patients with a high 
risk of opportunistic infections or cancer and in young 
male patients at risk of hepatosplenic T cell lymphoma. 
Especially in countries with a high prevalence of TB, such 
as Korea, China, and India, the risk of TB needs to be 
considered when selecting a therapeutic drug. VDZ is 
expected to be a very low­risk drug in this regard, with 
only 4 TB cases out of approximately 3000 patients who 
received VDZ (0.1%). Another advantage of VDZ is that 
it can be used even in the presence of comorbidities that 
contraindicate anti­TNF therapy, such as demyelinating 
disease, congestive heart failure, and lymphoma.
Nevertheless, due to the gut selectivity of VDZ, it 
may not be expected to be effective in patients with 
extraintestinal symptoms. Recently, a case of CD invol­
ving the pleura and lungs after 3 doses of VDZ has been 
reported[40]. After isolating peripheral blood mononuclear 
cells from the patient, flow cytometry revealed an upre­
gulation of β1 integrin, which is required for homing 
of lymphocytes to the lungs, and the condition of the 
patient improved after prednisolone treatment. This 
shows that the shift in integrin expression triggered by 
VDZ can cause immune cells to migrate to organs other 
than the gut, thereby increasing the risk of extraintestinal 
autoimmune manifestations in CD. 
Anti­VDZ antibodies (AVAs) were detected in 56 out 
of 1434 patients (4%) who were treated with VDZ up to 
week 52 in the GEMINI 1 and 2 trials, but of these, only 
9 patients (0.6%) continued to show AVA positivity, and 
33 patients (2.6%) developed neutralizing antibodies[38]. 
In the GEMINI LTS trial, the immunogenicity rate did 
not increase over time. When VDZ was administered 
in combination with immunosuppressants at baseline, 
the AVA positivity rate was 3%, which was 1% lower 
than the AVA positivity rate of 4%. However, these 
measurements were taken when the patients had a 
high serum drug concentration, which could have inter­
fered with the assay. Therefore, VDZ seems to have 
low immunogenicity and could be used without immu­
nosuppressants; however, further research is required.
VDZ may be expected to have a positive effect on 
fistula closure rate in CD. The phase IV ENTERPRISE 
trial (NCT02630966), which is currently underway, 
focuses on fistula healing at week 30 after 22 wk of VDZ 
medication in patients with fistulizing CD.
Research on combination therapy has so far been 
limited to case reports. One report found that VDZ 
+ etanercept, the soluble TNF receptor, combination 
therapy is effective at controlling severe pouchitis and 
spondylarthritis that developed in a patient with UC; one 
UC patient who showed no response to treatment with 
methotrexate, adalimumab, infliximab, azathioprine, 
cyclosporine A, or golimumab showed clinical remission 
and mucosal healing when treated with a combination of 
VDZ + certolizumab pegol and monitored for 21 mo[41,42]. 
These reports indicate that combination therapy using 
VDZ and an anti­TNF agent can provide additional clinical 
benefits, and an open­label study is currently underway 
to examine the effects of three­drug combination therapy 
using VDZ, adalimumab, and methotrexate in high­risk 
CD patients (NCT02764762).
Recently, a study was published on biomarkers that 
can predict response to VDZ[43]. Using VDZ labeled 
with fluorescein isothiocyanate, α4β7­expressing cells 
were detected by confocal laser endomicroscopy; 
clinical response and endoscopic remission to VDZ were 
observed in patients who showed pericryptal α4β7+ cells 
in the mucosa, whereas patients without α4β7+ cells did 
not respond to VDZ. 
Abrilumab
Abrilumab (AMG 181/MEDI 7183) is a fully human 
monoclonal IgG2 antibody against α4β7 integrin that 
has recently been used in several clinical trials.
In a phase Ⅱb study to evaluate the efficacy and 
safety of abrilumab in 354 moderate­to­severe UC pa­
tients who showed an inappropriate response or LOR 
to anti­TNFs, immunomodulators, or corticosteroid 
Anti-TNF therapy Gut-specific anti-integrin therapy
Mechanism of action TNF-α inhibitor α4β7-integrin inhibitor
Available agents Infliximab (UC, CD) Vedolizumab (UC, CD)
Adalimumab (UC, CD)
Certolizumab pegol (CD)
Golimumab (UC)
Therapeutic efficacy Frequent loss of response during maintenance therapy Modest effect on induction therapy for CD
Side effects Infections, reactivation of latent tuberculosis, potential risk of lymphoma Nasopharyngitis, arthralgia, headache, nausea
Immunogenicity Measure the ADA if available No significant immunogenicity
Add immunomodulator (infliximab)
Table 2  Comparison of properties of anti-tumor necrosis factor and gut-specific anti-integrin therapy
TNF: Tumor necrosis factor; UC: Ulcerative colitis; CD: Crohn’s disease; ADA: Antidrug antibodies.
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therapy, patients were divided into a placebo group, 
groups receiving subcutaneous abrilumab 7, 21, or 70 
mg at weeks 0, 2, and 4, followed by its administration 
once every four weeks, and a group receiving a single 
subcutaneous 210 mg dose of abrilumab[44]. The primary 
endpoint, which was remission rate at week 8, was 
1.6%, 2.9%, 13.5%, and 13.4% in the abrilumab 7 mg, 
21 mg, 70 mg, and 210 mg groups, respectively, and 
was 4.4% in the placebo group; the abrilumab 70 mg 
group (P = 0.021) and 210 mg group (P = 0.030) both 
showed a significantly higher remission rate than the 
placebo group. Abrilumab increased α4β7­high central 
memory CD4+ T cell counts in the peripheral blood, and 
high trough abrilumab concentrations were associated 
with increased remission rate. No PML or severe 
adverse events were observed in the abrilumab groups 
through week 24 and no patients developed neutralizing 
antibodies to abrilumab. Thus, abrilumab showed 
advantageous pharmacokinetics, pharmacodynamics, 
very low immunogenicity, and an acceptable safety 
profile; further results are expected in the future.
A phase Ⅱb trial was conducted to evaluate the 
efficacy and safety of abrilumab in 249 patients with 
moderate­to­severe CD who showed evidence of active 
inflammation and an inappropriate response, LOR, 
or intolerance to immunosuppressants, anti­TNFs, or 
corticosteroid therapy[45]. Patients were divided into a 
placebo group and groups receiving abrilumab 21 mg 
or 70 mg at weeks 0, 2, and 4, followed by once every 
four weeks, and a group receiving a single 210 mg dose 
of abrilumab. The primary endpoint, which was CDAI 
remission (CDAI score of < 150 points) rate at week 
8, was 23.1%, 14.4%, and 21.9% in the abrilumab 
21 mg, 70 mg, and 210 mg groups, respectively, and 
12.8% in the placebo group; there were no statistically 
significant differences between the abrilumab groups 
and the placebo group. However, among patients who 
had previously experienced anti­TNF treatment failure, 
CDAI remission rates at week 12 were 22.9%, 17.4%, 
and 24.8% in the abrilumab 21 mg, 70 mg, and 210 
mg groups, respectively, which were all significantly 
higher than the remission rate of 8.2% in the placebo 
group (P < 0.01). Also, in patients with prior anti­TNF 
failure, the CDAI response (decrease of at least 100 
points in CDAI score compared to baseline) rates at 
week 12 in the abrilumab 21 mg, 70 mg, and 210 mg 
groups were 30.0%, 39.4%, and 37.4%, respectively, 
and these values in the abrilumab 70 mg and 210 mg 
groups were significantly higher than the response rate 
of 14.2% in the placebo group (P < 0.01). Adverse 
events up to week 24 were the same in the abrilumab 
groups and the placebo group, and there were no cases 
of PML or death in any of the abrilumab groups. Thus, 
in CD, although abrilumab did not show a significant 
improvement in the primary endpoint, it could show 
useful effects.
Etrolizumab
Etrolizumab (rhuMAb β7) is a humanized monoclonal 
IgG1 antibody against the β7 subunit of α4β7 and αEβ7 
that blocks not only the interaction between α4β7 and 
MAdCAM­1, but also the interaction between αEβ7 and 
E­cadherin expressed mostly by epithelial cells. Thus, 
etrolizumab suppresses the trafficking of lymphocytes 
into the gut and the retention of lymphocytes in the 
intraepithelial compartment.
The phase Ⅱ EUCALYPTUS induction study was 
conducted on 124 moderate­to­severe UC patients 
who showed no response to conventional therapy[46]. 
Patients were randomly allocated in a 1:1:1 ratio into 
a placebo group, a group administered subcutaneous 
etrolizumab 100 mg at weeks 0, 4, and 8 (and placebo 
at week 2), and a group administered a loading dose 
(LD) of subcutaneous etrolizumab 420 mg, followed 
by subcutaneous doses of 300 mg at weeks 2, 4, and 
8. The primary endpoint, which was clinical remission 
rate at week 10, was 0% in the placebo group, 20.5% 
in the etrolizumab 100 mg group (P = 0.004), and 
10.3% in the etrolizumab 300 mg plus LD group (P = 
0.048); the clinical remission rate was higher in the 
etrolizumab groups than in the placebo group. In a 
subgroup analysis, among anti­TNF­naïve patients, 
the clinical remission rates in the etrolizumab 100 mg 
group and the etrolizumab 300 mg plus LD group were 
44% and 25%, respectively; however, among patients 
who had not responded to anti­TNF therapy, the clinical 
remission rates were 5% and 4%. Although there were 
no cases of severe infection in the etrolizumab­treated 
groups, and there was no significant difference in the 
rate of adverse reactions sufficient to stop medication 
in the three groups, influenza­like illness (7% vs 0% 
and 2%) arthralgia (15% vs 5% and 9%), and rash 
(7% vs 3% and 2%) were observed more frequently 
in the etrolizumab 100 mg group than the etrolizumab 
300 mg plus LD group or the placebo group. However, 
these adverse events were all mild or moderate, 
demonstrating that etrolizumab is safe and tolerable.
One notable aspect of this study is that when quan­
titative PCR and immunohistochemistry were used to 
measure the number of αE gene (ITGAE)­expressing 
and αE­positive cells in the colonic mucosa, higher 
αE expression was associated with a higher rate of 
clinical remission at week 10 in patients treated with 
etrolizumab, suggesting that αE expression could be 
used as a biomarker in etrolizumab treatment[46]. The 
subsequent study was conducted on colon tissues 
taken by biopsies from the UC patients in this phase 
Ⅱ trial, as well as the patients with UC and a control 
group without IBD in an observational study[47]. Here, 
the mRNA for granzyme A (GZMA), a serine protease 
that promotes cell migration and is associated with the 
secretion of inflammatory cytokines such as IL­1β and 
TNF­α, showed high expression in colonic CD4+ integrin 
αE+ cells; higher levels of GZMA mRNA or ITGAE mRNA 
were associated with a higher likelihood of responding 
to etrolizumab, and their expression after etrolizumab 
treatment decreased significantly by 40%­80%. 
Currently, there are 5 ongoing phase Ⅲ randomized 
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controlled trials (HIBISCUS Ⅰ, HIBISCUS Ⅱ, GARDENIA, 
LAUREL, and HICKORY) and 1 rollover open­label 
extension trial (COTTONWOOD) on UC.
The phase Ⅲ BERGAMOT trial aimed to evaluate 
the safety and efficacy of etrolizumab in 300 moderate­
to­severe CD patients who were previously refractory 
or intolerant to anti­TNFs, immunomodulators, and/or 
corticosteroid therapy[48]. The patients were randomly 
allocated in a ratio of 1:2:2 into a placebo group, a group 
receiving subcutaneous etrolizumab 105 mg every four 
weeks, and a group receiving subcutaneous etrolizumab 
210 mg at weeks 0, 2, 4, 8, and 12. The symptomatic 
remission (abdominal pain ≤ 1 and unweighted stool 
frequency ≤ 3) rates at week 6 were 15.0% and 25.6% 
in the etrolizumab 105 mg and etrolizumab 210 mg 
groups, respectively, which were higher than the rate of 
8.5% in the placebo group. Similarly, the symptomatic 
remission rates at week 10 were higher in the etroli­
zumab 105 mg and etrolizumab 210 mg groups, at 
15.8% and 27.3%, than the placebo group, at 8.5%, and 
the symptomatic remission rates at week 14 were still 
higher in the etrolizumab 105 mg and 210 mg groups, at 
20.8% and 24.8%, than in the placebo group, at 11.9%. 
The endoscopic improvement (decrease of at least 50% 
in SES­CD compared to baseline) rates at week 14 were 
also higher in the etrolizumab 105 mg and 210 mg 
groups, at 21.0% and 17.4%, than in the placebo group, 
at 3.4%. There were no significant differences between 
the placebo group and the etrolizumab groups in adverse 
events. Thus, etrolizumab showed a rapid effect at 
week 6 in the treatment of moderate­to­severe CD, and 
research is underway investigating the maintenance 
phase.
The phase Ⅲ HICKORY open­label induction trial 
aimed to investigate the efficacy of etrolizumab in 130 
moderate­to­severe UC patients who showed intolerance 
or no response to anti­TNFs[49]. After patients were 
administered etrolizumab 105 mg by subcutaneous 
injections for 14 wk, at four­week intervals, the clinical 
response and remission rates at week 14 were 50.8% 
and 12.3%, respectively, and 43.9% of patients receiving 
etrolizumab showed an endoscopic improvement, repre­
sented by a decrease of at least 1 point in endoscopy 
score compared to baseline. HICKORY including double 
blind induction phase and maintenance phase is currently 
ongoing (NCT02100696). 
αEβ7 and α4β7 are differentially expressed in T 
lymphocyte effector subsets in the peripheral blood and 
intestines of IBD patients; T cell receptor stimulation and 
transforming growth factor­β treatment increased the 
expression of αEβ7, especially in CD8+ lymphocytes[50]. 
When used in a humanized mouse model of colitis, 
etrolizumab surrogate antibody decreased the accu­
mulation of CD8+ and CD4+ Th9 cells in the intestine 
more strongly than VDZ; this seems to be because 
etrolizumab had an additional inhibitory effect on the 
αEβ7­mediated retention of lymphocytes[50]. 
If β7 integrin is blocked, it could reduce gut speci­
ficity; this is because αEβ7 is expressed by T cells in 
other tissues as well as in the intestines; therefore, 
problems can arise with the control of local infection[51]. 
Therefore, in the ongoing phase Ⅲ trials, it is important 
to determine whether latent infection is a significant 
adverse effect of etrolizumab. 
PF-00547659 
PF­00547659 (SHP647) is a fully human monoclonal 
IgG2κ antibody targeting MAdCAM­1, an intestinal 
endothelial CAM that binds α4β7 integrin on lymphocytes. 
This is another strategy for inhibiting leukocyte adhesion 
by blocking the endothelial CAM from binding to the 
integrin ligand.
The phase Ⅱ TURANDOT trial analyzed 357 mode­
rate­to­severe UC patients who had either shown failure 
or intolerance for at least one conventional therapy[52]. 
PF­00547569 was administered every four weeks by 
subcutaneous injection at either one of the 4 different 
doses (7.5, 22.5, 75, or 225 mg) and the outcomes 
were compared with a placebo. The primary endpoint, 
which was clinical remission rate at week 12, was 2.7% 
in the placebo group, 11.3% in the PF­00547569 7.5 
mg group (P = 0.0425), 16.7% in the 22.5 mg group 
(P = 0.0099), 15.5% in the 75 mg group (P = 0.0119), 
and 5.7% in the 225 mg group (P = 0.1803), indicating 
that the remission rate was significantly higher in the 
PF­00547569 7.5 mg, 22.5 mg, and 75 mg groups than 
in the placebo group, and the efficacy was the highest 
in the 22.5 mg and 75 groups. The mucosal healing 
rate at week 12 was 8.2% in the placebo group, 15.5% 
in the 7.5 mg group (P = 0.0099), 27.8% in the 22.5 
mg group (P = 0.0038), 25.4% in the 75 mg group 
(P = 0.0080), and 14.3% in the 225 mg group (P = 
0.0099), showing the highest value in the PF­00547569 
22.5 mg and 75 mg groups. In a subgroup analysis, 
among patients experiencing anti­TNF therapy failure, 
the remission rate at week 12 was 0% in the placebo 
group, 7.3% in the 7.5 mg group (P = 0.0425), 9.8% 
in the 22.5 mg group (P = 0.0099), 9.8% in the 75 mg 
group (P = 0.0119), and 2.5% in the 225 mg group 
(P = 0.1803), showing significantly higher values than 
the placebo group in the PF­00547569 7.5 mg, 22.5 
mg, and 75 mg groups. The reason that the clinical 
effect of PF­00547659 at the highest dose decreased 
may be because of study design or the depletion of the 
anti­inflammatory regulatory T cells to the intestine, 
and further research is needed[53]. There were no 
significant differences between the placebo group and 
the PF­00547569 groups in the frequency of adverse 
events, and there were no cases of severe infection or 
PML. When GI side effects were investigated considering 
the gut selectivity of PF­00547659, Clostridium difficile 
infection, anal abscess and anal fistula were observed 
in patients treated with PF­00547659 and one patient 
was diagnosed with adenocarcinoma of colon during the 
study period. Therefore, special attention should be paid 
to GI complications in the treatment of PF­00547659, 
and additional data is necessary to establish its safety. A 
large­scale phase Ⅲ clinical trial is currently underway in 
Park SC et al . Anti­integrin therapy for IBD
1878 May 7, 2018|Volume 24|Issue 17|WJG|www.wjgnet.com
patients with UC (NCT03259334).
The phase Ⅱ OPERA trial aimed to evaluate the 
efficacy and safety of PF­00547569 in 265 moderate­
to­severe CD patients who had previously shown no 
response or intolerance for anti­TNFs and/or immu­
nosuppressants[54]. Patients were randomly allocated, in 
a 1:1:1:1 ratio, to a placebo group and groups receiving 
PF­00547569 at either one of the 3 doses (22.5, 75, or 
225 mg). The CDAI­70 response rates at week 8 showed 
no significant differences, at 47.7% in the placebo group 
and 52.7%, 60.1%, and 62.7% in the PF­00547569 
22.5, 75, and 225 mg groups, respectively. Similarly, 
the CDAI­70 response rates at week 12 also showed no 
significant differences, at 58.6% in the placebo group 
and 62.8%, 64.7%, and 57.5% in the PF­00547569 
22.5, 75, and 225 mg groups, respectively. However, 
among patients with high baseline CRP levels (> 5 mg/dL 
or > 18.8 mg/dL), the CDAI remission rates at week 8 or 
12 were higher in the PF­00547569 groups than in the 
placebo group. Moreover, in the PF­00547569 groups, 
soluble MAdCAM level decreased significantly at week 2 
in a dose­dependent manner and circulating β7+ CD4+ 
central memory T lymphocytes increased at weeks 8 and 
12. Therefore, although the high clinical response rate in 
the placebo group indicated that there was no significant 
difference between the PF­00547569 groups and the 
placebo group, PF­00547569 seems to be effective in 
patients with active inflammation. 
Given the clinical success of drugs that block α4β7 
integrin, antibodies against MAdCAM­1 should produce 
a similar clinical effect. However, this is not reflected 
in the study results because α4β7 not only binds 
MAdCAM­1, but also has epitopes for binding VCAM­1 
and fibronectin, though it is known that VDZ does not 
affect the adhesion of α4β7 to VCAM­1[55]. 
CONCLUSION
The introduction of anti­TNF drugs in IBD treatment 
demonstrated superior therapeutic effects compared 
to conventional treatment. However, the development 
of new drugs is required for several reasons, including 
inadequate response, LOR or intolerance. The aim of 
developing new treatments for UC and CD is to produce 
targeted drugs that can enhance the clinical effect while 
reducing systemic adverse events. In this regard, anti­
integrin agents are one of the most promising drug 
classes for IBD after anti­TNF agents. Anti­integrin 
agents inhibit the extravasation of lymphocytes by 
blocking the interactions between integrin and CAMs. 
The use of the initially developed natalizumab is limited 
use due to the risk of PML; however, VDZ developed later 
acts selectively on the intestine and shows few systemic 
adverse effects. VDZ has been approved and is currently 
used in clinical practice. Newer anti­integrin drugs that 
act on different targets associated with integrin, such as 
AJM300, abrilumab, etrolizumab, and PF­00547659 are 
also being developed and currently undergoing clinical 
trials. 
In the future, clinical trials of anti­integrin drugs are 
expected to demonstrate their clinical efficacy, their place 
in the treatment of IBD, and their associated adverse 
effects. This will widen the range of drugs available 
to physicians and patients for treating IBD, and is an 
important step toward truly personalized treatment.
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